Della Corte Luigi, Cafasso Valeria, Boccia Dominga, Morra Ilaria, De Angelis Carmine, De Placido Sabino, Giampaolino Pierluigi, Di Carlo Costantino, Bifulco Giuseppe
Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, 84014 Naples, Italy.
Department of Public Health, School of Medicine, University of Naples Federico II, 84014 Napoli, Italy.
J Pers Med. 2023 Jan 29;13(2):240. doi: 10.3390/jpm13020240.
Since February 2020, the spread of Coronavirus Disease 2019 (COVID-19) in Italy has induced the government to call for lockdown of any activity apart from primary needs, and changing the lives of each of us. All that has dramatically impacted the management of patients affected by cancer. Patients with vulvar cancer (VC) represent a particularly frail population because they are elderly and affected by multiple comorbidities. The aim of this study is to evaluate the clinical impact of the SARS-CoV-2 infection on VC patients in terms of delay or impossibility of carrying out the scheduled treatment. The medical records of patients affected by vulvar tumors, referred to "DAI Materno-Infantile" of AOU Federico II of Naples between February 2020 and January 2022 were retrospectively analyzed. The presence of a positive reverse transcription-polymerase chain reaction (RT-PCR) in nasopharyngeal swab defined the positivity to SARS-CoV-2. Twenty-four patients with VC were analyzed and scheduled for treatment. The median age was 70.7 years (range: 59-80). Seven (29.2%) patients were diagnosed with SARS-CoV-2 infection: In three (42.8%) patients, the treatment was delayed with no apparent consequences, in four (57.2%), the treatment was delayed or changed due to cancer progression and, of these four, one died due to respiratory complications of COVID-19, and one died due to oncologic disease progression. COVID-19 caused, in most cases, significant delays in oncologic treatments and high mortality in our series of patients affected by VC.
自2020年2月以来，2019冠状病毒病（COVID-19）在意大利的传播促使政府呼吁除基本需求外的任何活动都实施封锁，这改变了我们每个人的生活。所有这些都对癌症患者的管理产生了巨大影响。外阴癌（VC）患者是一个特别脆弱的群体，因为他们年事已高且患有多种合并症。本研究的目的是评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染对VC患者在实施预定治疗方面的延迟或无法进行治疗的临床影响。回顾性分析了2020年2月至2022年1月期间转诊至那不勒斯费德里科二世大学医院“母婴医院”的外阴肿瘤患者的病历。鼻咽拭子中逆转录聚合酶链反应（RT-PCR）呈阳性确定为SARS-CoV-2阳性。分析了24例VC患者并安排了治疗。中位年龄为70.7岁（范围：59 - 80岁）。7例（29.2%）患者被诊断为SARS-CoV-2感染：3例（42.8%）患者的治疗延迟但无明显后果，4例（57.2%）患者的治疗因癌症进展而延迟或改变，在这4例患者中，1例因COVID-19的呼吸并发症死亡，1例因肿瘤疾病进展死亡。在我们这组VC患者中，COVID-19在大多数情况下导致了肿瘤治疗的显著延迟和高死亡率。
